Figure 2.

Antineoplastic effects of TNKS inhibitors in vitro. Treatments with TNKS inhibitors XAV939, IWR-1 endo, and IWR-1 exo exerted antineoplastic effects against NSCLC cell lines in vitro, as compared to vehicle controls. (A) Cell proliferation dose-response curves for the three TNKS inhibitors against ED1 (left panel), ED1L (middle panel), and ED2 (right panel) murine lung cancer cell lines as compared to vehicle control are shown, as measured by luminescent cell viability assay after 3 days. (B) Cell proliferation dose-response relationships for the three TNKS inhibitors against A549 (left panel), Hop62 (middle panel), and H522 human NSCLC cell lines as compared to vehicle control are shown, using the same luminescent cell viability assay and 3 day time frame. (C) Dose-response curves show antiproliferative effects of the three TNKS inhibitors against the immortalized bronchial epithelial cell lines C-10 (murine) and BEAS-2B (human) versus vehicle control. (D) Ten-day colony formation is shown for the ED1 cell line following individual treatment with 10 μM of each TNKS inhibitor or vehicle control (left two images), and quantified (right panel). Error bars represent standard deviations of three experiments in triplicate. (* p ≤ 0.05).

Busch et al. BMC Cancer 2013 13:211   doi:10.1186/1471-2407-13-211
Download authors' original image